Oxytocin and obesity
Authors:
K. Pozorčiaková 1; M. Kostková 1; J. Vojtková 1; M. Čiljaková 1,2; Peter Bánovčin 1
Authors‘ workplace:
Klinika detí a dorastu, JLF UK a UNM, Martin, Slovensko
1; Detské oddelenie NEDÚ, Ľubochňa, Slovensko
2
Published in:
Čes-slov Pediat 2020; 75 (1): 40-45.
Category:
Review
Overview
Obesity is a serious illness affecting children not only in developed but also in developing countries. Obesity leads to many serious complications that can lead to a shortened life span of the patient and a decrease in quality of life. It is necessary to pay attention to this disease in childhood, because obesity in children predisposes to obesity in adulthood.
Oxytocin is a hormone that is synthesized in the hypothalamus and is known mainly for its effects in childbirth and lactation. Nowadays there is a focus on oxytocin involvement in metabolism - its effect on insulin secretion, lipolysis and food intake. Changes in concentration of oxytocin have been reported in obese patients. Intranasal administration of oxytocin appears to be a possible therapeutic method of obesity treatment. Recent studies have shown weight loss, improvement in glucose and lipid metabolism following oxytocin administration, and no serious adverse effects have been reported yet.
Keywords:
obesity – Oxytocin – metabolic syndrome
Sources
1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384 (9945): 766–781.
2. WHO. Obesity and overweight. 2016. http://who.int/mediacentre/factsheets/fs311/en/.
3. De Onis M., Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010; 92 (5): 1257–1264.
4. OECD. Obesity update. 2017. http://www.oecd.org/health/health-systems/Obesity-Update-2017.pdf.
5. OECD. Overweight and obesity among children. Health at a Glance 2017: OECD Indicators, OECD Publishing, Paris. https://doi.org/10.1787/health_glance-2017-22-en.
6. Hainer V, et al. Základy klinické obezitologie. 2. prepracované a doplnené vyd. Praha: Grada Publishing, 2011.
7. Toschke AM, Vignerova J, Lhotska L, et al. Overweight and obesity in 6- to 14-year-old Czech children in 1991: protective effect of breast--feeding. J Pediatr 2002; 141 (6): 764–769.
8. Czippelová B, Turianiková Z, Krohová J, et al. Arterial stiffness in obese adolescents – a relation to vascular resistance and sympathetic nervous system activity. Acta Physiol 2017; 221: Suppl: S713.
9. Durdík P, Sujanska A, Suroviakova S, et al. Sleep architecture in children with common phenotype of obstructive sleep apnea. J Clin Sleep Med 2018; 14 (1): 9–14.
10. Šujanská A, Ďurdík P, Suroviaková S, et al. Chrápanie u detí predškolského a školského veku. Lek Obz 2016; 65 (11): 412–417.
11. Suroviaková S, Šujanská A, Ďurdík P, et al. Centrálne spánkove apnoe u detí. Lek Obz 2016; 65 (11): 433–437.
12. Pražienková V, Holubová M, Pelantová H, et al. Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity. PLoS One 2017; 12 (8): e0183449.
13. Javorka K, et al. Lekárska fyziológia. Tretie, prepracované a doplnené vydanie. Martin: Osveta, 2009.
14. Lane N. Oxygen: The Molecule that Made the World. Oxford: Oxford University Press, 2002.
15. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001; 81 (2): 629–683.
16. Kiss A, Mikkelsen JD. Oxytocin – anatomy and functional assignments: a minireview. Endocr Regul 2005; 39 (3): 97–105.
17. NCBI. LNPEP leucyl and cystinyl aminopeptidase [Homo sapiens (human)]. 2019. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=4012.
18. Fjellestad-Paulsen A, Lundin S. Metabolism of vasopressin, oxytocin and their analogues [Mpa1, D-Arg8]-vasopressin (dDAVP) and [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (anatocin) in human kidney and liver homogenates. Regul Pept 1996; 67 (1): 27–32.
19. Smith R. Parturition. N Engl J Med 2007; 356 (3): 271–283.
20. Yang HP, Wang L, Han L, et al. Nonsocial functions of hypothalamic oxytocin. ISRN Neuroscience 2013. doi: 10.1155/2013/179272.
21. Ho JM, Blevins JE. Coming full circle: Contributions of central and peripheral oxytocin actions to energy balance. Endocrinology 2013; 154 (2): 589–596.
22. Deblon N, Veyrat-Durebes C, Bourgoin L, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induces obese rats. PLoS One 2011; 6 (9): e25565.
23. Morton GJ, Thatcher BS, Reidelberger RD, et al. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 2012; 302: E124–E144.
24. Blevins JE, Graham JL, Morton GJ, et al. Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 2015; 308: R431–R438.
25. Klement J, Ott V, Rapp K, et al. Oxytocin improves β-cell responsivity and glucose tolerance in healthy men. Diabetes 2017; 66 (2): 264–271.
26. Elabd SK, Sabry I, Mohasseb M, et al. Oxytocin as a novel therapeutic option for type I diabetes and diabetic osteopathy. Endocr Regul 2014; 48 (2): 87–102.
27. Zhang H, Wu C, Chen Q, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One 2013; 8: e61477.
28. Maejima Y, Iwasaki Y, Yamahara Y, et al. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Albany NY) 2011; 3 (12): 1169–1177.
29. Zhang G, Bai H, Zhang H, et al. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron 2011; 69 (3): 523–535.
30. Watanabe S, Wei FY, Matsunaga T, et al. Oxytocin protects against stress-induced cell death in murine pancreatic β-cells. Sci Rep 2016; 6: 25185.
31. Altirriba J, Poher AL, Caillon A, et al. Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology 2014; 155 (11): 4189–4201.
32. Perello M, Raingo J. Leptin activates oxytocin neurons of the hypothalamic paraventricular nucleus in both control and diet-induced obese rodents. PLoS One 2013; 8 (3): e59625.
33. Altirriba J, Poher AL, Rohner-Jeanrenaud F. Chronic oxytocin administration as a treatment against impaired leptin signaling or leptin resistance in obesity. Front Endocrinol (Lausanne) 2015; 6: 119.
34. Plante E, Menaouar A, Danalache BA, et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology 2015; 156 (4): 1416–1428.
35. Husarova VM, Lakatosova S, Pivovarciova A, et al. Plasma oxytocin in children with autism and its correlations with behavioral parameters in children and parents. Psychiatry Investig 2016;13 (2): 174–183.
36. Ozsoy S, Esel E, Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009; 169 (3): 249–252.
37. Kaye WH. Neuropeptide abnormalities in anorexia nervosa. Psychiatry Res 1996; 62 (1): 65–74.
38. Lawson EA, Donoho DA, Blum JI, et al. Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. J Clin Psychiatry 2011; 72 (11): 1546–1551.
39. Afinogenova Y, Schmelkin C, Plessow F, et al. Low fasting oxytocin levels are associated with psychopathology in anorexia nervosa in partial recovery. J Clin Psychiatry 2016; 77 (11): e1483–e1490.
40. Hoffman ER, Brownley KA, Hamer RM, et al. Plasma, salivary, and urinary oxytocin in anorexia nervosa: a pilot study. Eat Behav 2012; 13 (3): 256–259.
41. Monteleone AM, Scognamiglio P, Volpe U, et al. Investigation of oxytocin secretion in anorexia nervosa and bulimia nervosa: Relationships to temperament personality dimensions. Eur Eat Disord Rev 2016; 24 (1): 52–56.
42. Qian W, Zhu T, Tang B, et al. Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J Clin Endocrinol Metab 2014; 99 (12): 4683–4689.
43. Gajdosechova L, Krskova K, Segarra AB, et al. Hypooxytocinaemia in obese zucker rats relates to oxytocin degradation in liver and adipose tissue. J Endocrinol 2014; 220 (3): 333–343.
44. Yuan G, Qian W, Pan R, et al. Reduced circulating oxytocin and high-molecular-weight adiponectin are risk factors for metabolic syndrome. Endocr J 2016; 63 (7): 655–662.
45. Binay Ç, Paketçi C, Güzel S, et al. Serum irisin and oxytocin levels as predictors of metabolic parameters in obese children. J Clin Res Pediatr Endocrinol 2017; 9 (2): 124–131.
46. Eisenberg Y, Dugas LR, Akbar A, et al. Oxytocin is lower in African American men with diabetes and associates with psycho-social and metabolic health factors. PLoS One 2018; 4 (13): e0190301.
47. Kujath AS, Quinn L, Elliott ME, et al. Oxytocin levels are lower in premenopausal women with type 1 diabetes mellitus compared with matched controls. Diabetes Metab Res Rev 2015; 31 (1): 102–112.
48. Schroeder M, Zahoory-Sharon O, Shbiro L, et al. Development of obesity in the Otsuka Long-Evans Tokushima Fatty rat. Am J Physiol Regul Integr Comp Physiol 2009; 297 (6): R1749–R1760.
49. Szulc P, Amri EZ, Varennes A, et al. High serum oxytocin is associated with metabolic syndrome in older men. Diabetes Res Clin Pract 2016; 122: 17–27.
50. Schorr M, Marengi DA, Pulumo RL, et al. Oxytocin and its relationship to body composition, bone mineral density, and hip geometry across the weight spectrum. J Clin Endocrinol Metab 2017; 102 (8): 2814–2824.
51. Al-Nouaaimi MM, Kasabri V, Akour A, et al. Evaluation of the correlation of oxytocin plasma levels and metabolic syndrome biomarkers (leptin, adiponectin and resistin) in newly diagnosed type 2 diabetes patients in Jordan: A cross sectional study. Jordan J Pharmaceutical Sciences 2016; 9 (2).
52. Al-Rawashdeh A, Kasabri V, Bulatova N, et al. The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan. Diabetes Metab Syndr 2016; 11 (1): 59–67.
53. Lawson EA, Ackerman KE, Slattery M, et al. Oxytocin secretion is related to measures of energy homeostasis in young amenorrheic athletes. J Clin Endocrinol Metab 2014; 99 (5): E881–E885.
54. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995; 80 (2): 573–579.
55. Bittel DC, Kibiryeva N, Dasouki M, et al. A 9-year-old male with a duplication of chromosome 3p25.3p26.2: Clinical report and gene expression analysis. Am J Med Genet A 2006; 140 (6): 573–579.
56. Johnson L, Manardo, AM, Miller JL, et al. Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings. Am J Med Genet A 2016; 170: 594–601.
57. Burnett LC, Leduc CA, Sulsona CR, et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J Clin Invest 2017; 127: 293–305.
58. Kuppens RJ, Donze SH, Hokkens-Koelega ACS. Promising effects of oxytocin on social and food-related behavior in your children with Prader-Willi syndrome: a randomised, double-blind, controlled crossover trial. Clin Endocrinol 2016; 85: 979–987.
59. Tauber M, Boulanouar K, Diene G, et al. The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome. Pediatrics 2017; 139: e20162976.
60. Akour A, Kasabri V, Bulatova N, et al. Association of oxytocin with glucose intolerance and inflammation biomarkers in metabolic syndrome patients with and without prediabetes. Rev Diabet Stud 2018; 14 (4): 364–371.
61. Hosny S, Bekhet M, Bahaaeldin A, et al. Serum oxytocin in elderly patiens with metabolic syndrome. Endocrine Abstracts 2018; 56: P564.
62. Blevins JE, Baskin DG. Translational and therapeutic potential of oxytocin as an anti-obesity strategy: insights from rodents, nonhuman primates and humans. Physiol Behav 2015; 152: 438–449.
63. Lawson EA, Marengi DA, DeSanti RL, et al. Oxytocin reduces caloric intake in men. Obesity 2015; 23 (5): 950–956.
64. Lee MR, Scheidweiler KB, Diao XX, et al. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin aasay. Mol Psychiatry 2018; 23 (1): 115–122.
65. Zhang G, Cai D. Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab 201; 301 (5): E1004–E1012.
66. Macdonald E, Dadds MR, Brennan JL, et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011; 36 (8): 1114–1126.
67. Anagnostou E, Soorya L, Bian J, et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res 2014; 1580: 188–198.
68. Miller JL, Tamura R, Butler MG, et al. Oxytocin treatment in children with Prader-Willi syndrome: a double-blind, placebo-controlled, crossover study. Am J Med Genet A 2017; 173: 1243–1250.
69. Kim YR, Eom JS, Yang JW, et al. The impact of oxytocin on food intake and emotion recognition in patients with eating disorders: A double blind single dose within-subject cross-over design. PLoS One 2015; 10 (9): e0137514.
70. Thienel M, Fritsche A, Heinrichs M, et al. Oxytocin‘s inhibitory effect on food intake is stronger in obese than normal-weight men. Int J Obes (Lond) 2016; 40 (11): 1707–1714.
71. Ott V, Finlayson G, Lehnert H, et al. Oxytocin reduces reward-driven food intake in humans. Diabetes 2013; 62 (10): 3418–3425.
72. Striepens N, Schröter F, Stoffel-Wagner B, et al. Oxytocin enhances cognitive control of food craving in women. Hum Brain Mapp 2016; 37 (12): 4276–4285.
73. Olszewski PK, Klockars A, Levine AS. Oxytocin and potential benefits for obesity treatment. Curr Opin Endocrinol Diabetes Obes 2017; 24 (5): 320–325.
74. Takayanagi Y, Kasahara Y, Onaka T, et al. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport 2008; 19 (9): 951–955.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2020 Issue 1
Most read in this issue
- It is never too late – HSV1-induced herepetic encephalitis
- Inherited arrhythmic syndromes in children
- Genetic causes of sudden infant death syndrome in the era of next generation sequencing.
- Expanded carrier screening of recessive disorders (CarrierTest) in clinical practice